Radcom

In this week's Globes review, we analyze the performance of Israeli stocks on Wall Street. Cybersecurity weakness wiped $1.3 billion off Check Point's valuation, Radcom shares plunged 20% following a guidance cut, and a failed clinical trial sent Karyopharm to an all-time low.